ReviewPharmaceutical research2015
Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy.
Review in Pharmaceutical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- The Application of Radiolabeled Mesoporous Silica Nanoparticles in Molecular Imaging.Molecules (Basel, Switzerland) · 2026Review
- Boron Theranostic Nanoplatform Utilizing a GO@Carborane@Au Hybrid Framework for Targeted Delivery.Pharmaceutics · 2026Article
- State-of-the-art boron clusters for boron neutron-capture therapy.Theranostics · 2026Review
- Boosting Boron Neutron Capture Therapy through Ferroptosis Activation with a Biomimetic Nanoenhancer.Biomaterials research · 2026Article
- Nucleoside Scaffolds and Carborane Clusters for Boron Neutron Capture Therapy: Developments and Future Perspective.Current medicinal chemistry · 2024Review
- Combined Gadolinium and Boron Neutron Capture Therapies for Eradication of Head-and-Neck Tumor Using GdJACS Au · 2023Article
- Dendritic Structures Functionalized with Boron Clusters, in Particular Carboranes, and Their Biological Properties.Pharmaceutics · 2023Review
- Sweet Battle of the Epimers─Continued Exploration of Monosaccharide-Derived Delivery Agents for Boron Neutron Capture Therapy.Molecular pharmaceutics · 2023Article
- Article
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Review
- Boron Neutron Capture Therapy: Current Status and Challenges.Frontiers in oncology · 2022Review
- Homocystamide Conjugates of Human Serum Albumin as a Platform to Prepare Bimodal Multidrug Delivery Systems for Boron Neutron Capture Therapy.Molecules (Basel, Switzerland) · 2021Article
- Design, Synthesis, and Biological Evaluation of Boron-Containing Macrocyclic Polyamines and Their Zinc(II) Complexes for Boron Neutron Capture Therapy.Journal of medicinal chemistry · 2021Article
- Theranostics in Boron Neutron Capture Therapy.Life (Basel, Switzerland) · 2021Review
- Evaluation of the correlation between porphyrin accumulation in cancer cells and functional positions for application as a drug carrier.Scientific reports · 2021Article
- Addressing the Biochemical Foundations of a Glucose-Based "Trojan Horse"-Strategy to Boron Neutron Capture Therapy: From Chemical Synthesis toMolecular pharmaceutics · 2020Article
- Article
- Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.Frontiers in chemistry · 2020Review
- Poly(vinyl alcohol) boosting therapeutic potential ofScience advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death. Since cellular destruction is limited to approximately the diameter of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged. However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron containing agents. While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clinical agents, new agents are desperately needed due to their suboptimal tumor selectivity. This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.
Indexed as
Identifiers
26033767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.